Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 16 2014
Print

Financial Reports: Alexion



Published April 25, 2013
Alexion 1Q13

1Q Revenues: $339 million (+38%)

1Q Earnings: $82 million (+81%)

Comments: Sales of Soliris climbed 38% to $339 million, adding patients for both paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) indications. R&D expenses climbed 64% to $75 million as the company advanced five clinical programs, including one with Soliris.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On